Systasy Bioscience GmbH

https://www.systasy.de

Systasy Bioscience GmbH is a provider of patient-centric innovative solutions for drug discovery and development with a focus on disorders of the brain. The company leverages highly multiplexed pathway activity screens and patient-derived human disease models to understand complex disease pathways. Systasy’s technology enables insights across the drug discovery pipeline, from the identification of novel targets and combinatorial drug screening to patient stratification. In addition, the Company offers viral tropism profiling for gene therapy development. Founded in 2012, Systasy Bioscience GmbH is committed to conquering even the most challenging diseases through scientific excellence and collaboration. *

	Start	2012-08-30 established
	Industry	reagents (bio/biochemical)
	Person	Wichert, Sven (Systasy Bioscience GmbH 201405 Managing Director + Co-Founder)

	Region	München (Munich)
	Country	Germany
	Street	6 Balanstr.
	City	81669 München
	Tel	+48-89-2155-3085
		Address record changed: 2024-07-31

Basic data	Employees	n. a.

		* Document for »About Section«: Systasy Bioscience GmbH. (7/31/24). "Press Release: Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical". Munich.

		Record changed: 2024-07-31

More documents for Systasy Bioscience GmbH

[1] Systasy Bioscience GmbH. (7/31/24). "Press Release: Systasy Bioscience Announces Collaboration Agreement with Ono Pharmaceutical". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]